News for VCNX Stock

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market Vaccinex Announces Receipt of Delisting Notification from Nasdaq Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024 Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024 Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update Vaccinex Reports 2023 Financial Results and Provides Corporate Update Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology Vaccinex, Inc. Announces Reverse Stock Split Vaccinex Announces Pricing of $3.7 Million PIPE Financing Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases Vaccinex Announces Pricing of $9.6 Million Public Offering Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer Vaccinex, Inc. Announces Reverse Stock Split Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells Vaccinex Announces Private Placement with Commitments of $5.0 Million Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology Vaccinex Announces $3.8 Million Private Placement Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery Vaccinex Reports 2021 Financial Results and Provides Corporate Update Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting Vaccinex Announces $6.6 Million Private Placement Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference Vaccinex to Present at the Virtual Huntington’s Study Group Meeting on November 4-6, 2021 Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington’s Disease Network Meeting Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting